Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:56 UTC |
---|
HMDB ID | HMDB0015293 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Terazosin |
---|
Description | Terazosin, also known as hytrin or terazosabb, belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. Terazosin is a very strong basic compound (based on its pKa). Terazosin is a potentially toxic compound. Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. It is available as a generic medication. It is taken by mouth. It is available in 1 mg, 2 mg, 5 mg or 10 mg doses. For high blood pressure, it is a less preferred option. A month supply in the United Kingdom costs the NHS less than 2 £ as of 2019. Prostate cancer should be ruled out before starting treatment. |
---|
Structure | COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1 InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) |
---|
Synonyms | Value | Source |
---|
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine | ChEBI | Terazosina | ChEBI | Terazosine | ChEBI | Terazosinum | ChEBI | Terazosabb | Kegg | Abbott 45975 | HMDB | Magnurol | HMDB | Nu-terazosin | HMDB | Ratio-terazosin | HMDB | Apo-terazosin | HMDB | Heitrin | HMDB | Hytrin | HMDB | Terazosin azu | HMDB | Terazosin hexal | HMDB | Terazosin hydrochloride | HMDB | Terazosina alter | HMDB | Terazosina kern | HMDB | Zayasel | HMDB | Adecur | HMDB | Deflox | HMDB | Dysalfa | HMDB | Flotrin | HMDB | Hytrine | HMDB | Novo-terazosin | HMDB | Sutif | HMDB | Tazusin | HMDB | Terazoflo | HMDB | Terazosin, monohydrochloride, dihydrate | HMDB | Hexal brand OF terazosin hydrochloride | HMDB | Hytrin BPH | HMDB | PMS-Terazosin | HMDB | Terazosina qualix | HMDB | Terazosin hydrochloride anhydrous | HMDB |
|
---|
Chemical Formula | C19H25N5O4 |
---|
Average Molecular Weight | 387.4329 |
---|
Monoisotopic Molecular Weight | 387.190654313 |
---|
IUPAC Name | 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine |
---|
Traditional Name | terazosin |
---|
CAS Registry Number | 63590-64-7 |
---|
SMILES | COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1 |
---|
InChI Identifier | InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) |
---|
InChI Key | VCKUSRYTPJJLNI-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazinanes |
---|
Sub Class | Piperazines |
---|
Direct Parent | N-arylpiperazines |
---|
Alternative Parents | |
---|
Substituents | - N-arylpiperazine
- Quinazolinamine
- Diazanaphthalene
- Quinazoline
- Anisole
- Dialkylarylamine
- Alkyl aryl ether
- Aminopyrimidine
- Pyrimidine
- Imidolactam
- Benzenoid
- Heteroaromatic compound
- Tetrahydrofuran
- Tertiary carboxylic acid amide
- Amino acid or derivatives
- Carboxamide group
- Carboxylic acid derivative
- Dialkyl ether
- Ether
- Oxacycle
- Azacycle
- Organic oxygen compound
- Amine
- Organic nitrogen compound
- Hydrocarbon derivative
- Carbonyl group
- Organonitrogen compound
- Organooxygen compound
- Primary amine
- Organopnictogen compound
- Organic oxide
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 273 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 1.5 g/L | Not Available | LogP | 1 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Terazosin,1TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N[Si](C)(C)C)=C2C=C1OC | 3784.8 | Semi standard non polar | 33892256 | Terazosin,1TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N[Si](C)(C)C)=C2C=C1OC | 3350.5 | Standard non polar | 33892256 | Terazosin,1TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N[Si](C)(C)C)=C2C=C1OC | 5321.7 | Standard polar | 33892256 | Terazosin,2TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 3758.5 | Semi standard non polar | 33892256 | Terazosin,2TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 3421.3 | Standard non polar | 33892256 | Terazosin,2TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 4962.8 | Standard polar | 33892256 | Terazosin,1TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 4009.6 | Semi standard non polar | 33892256 | Terazosin,1TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3570.7 | Standard non polar | 33892256 | Terazosin,1TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 5258.5 | Standard polar | 33892256 | Terazosin,2TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 4131.6 | Semi standard non polar | 33892256 | Terazosin,2TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3866.5 | Standard non polar | 33892256 | Terazosin,2TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 4897.7 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Terazosin GC-MS (Non-derivatized) - 70eV, Positive | splash10-00di-9375000000-51e0b50a02ca9182132a | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Terazosin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Terazosin LC-ESI-qTof , Positive-QTOF | splash10-000i-0049000000-86650e3e374df663aa35 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Terazosin , positive-QTOF | splash10-000i-0049000000-86650e3e374df663aa35 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Terazosin , positive-QTOF | splash10-000i-0059000000-ca9adf5daab9e5e9b6e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Terazosin , positive-QTOF | splash10-000e-1292000000-9081c5bb64e8d096db78 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Terazosin 35V, Negative-QTOF | splash10-0079-0019000000-d7e59834a3bdfe524c51 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Terazosin 35V, Positive-QTOF | splash10-000l-0097000000-c8329e54acf1c8a72d7c | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 10V, Positive-QTOF | splash10-000i-0029000000-b9509509936fd20822e4 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 20V, Positive-QTOF | splash10-007c-3069000000-196d536a1f876cf3fe0f | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 40V, Positive-QTOF | splash10-006t-2090000000-f24db01089337864b16f | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 10V, Negative-QTOF | splash10-000i-1019000000-f4c3728d09b25d55b2f4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 20V, Negative-QTOF | splash10-00dr-6098000000-81e55b539bff87910453 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 40V, Negative-QTOF | splash10-00em-3091000000-b40b6a5be295255d01ea | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 10V, Positive-QTOF | splash10-000i-0009000000-6fee4cbd3c043ea0f36a | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 20V, Positive-QTOF | splash10-000i-0009000000-0967bc8cd13ea8732283 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 40V, Positive-QTOF | splash10-006y-3149000000-56db17d16ac03814def3 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 10V, Negative-QTOF | splash10-000i-0009000000-8d31d2aa0ab8d99cf8d7 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 20V, Negative-QTOF | splash10-001r-0019000000-55003a7c1cdca21b9dfd | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Terazosin 40V, Negative-QTOF | splash10-001v-0197000000-499a38ef1791a534e75c | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]
|
---|